Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

MERS vaccine shows promise in phase 2 trial

NCT ID NCT04588428

First seen Jan 27, 2026 · Last updated May 15, 2026 · Updated 15 times

Summary

This study tested a new vaccine called INO-4700 to prevent MERS, a serious respiratory virus. It involved 192 healthy adults who received either the vaccine or a placebo. The goal was to check if the vaccine is safe and triggers an immune response. The vaccine was given as a shot followed by a quick electrical pulse to help it work better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-COV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ahero Clincal Trials Unit

    Kisumu, 40100, Kenya

  • American University of Beirut Medical Center

    Beirut, Lebanon

  • Clinical Research Center, Irbid Specialty Hospital (CRC/ISH)

    Irbid, 21110, Jordan

  • Hammoud Hospital University Medical Center

    Saida, Lebanon

  • Kenya Medical Research Institute (KEMRI)/Walter Reed Project (WRP)

    Kericho, 20200, Kenya

  • Pharmaceutical Research Center / Jordan University of Science and Technology

    Irbid, 22110, Jordan

Conditions

Explore the condition pages connected to this study.